- Zacks via Yahoo FinanceOct 14 23:04 PM
Johnson & Johnson JNJ is set to report their third quarter results as pending lawsuits loom over the company. The pharmaceutical giant’s shares have barely moved in 2019 thus far, rising only ...
- 247wallst.com10 hours ago
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related...Barron s Online3 days ago
Aesthetic Devices Market 2019 Global Analysis By Share, Size, Growth, Trends And Regional Forecast To 2024 - MRE AnalysisMarket Watch12 hours ago
The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune...Benzinga via Yahoo FinanceOct 09 11:58 AM
Biotech stocks that hit 52-week lows Oct. 8. ABIOMED, Inc. NASDAQ: ABMD) Adamas Pharmaceuticals Inc (NASDAQ: ADMS) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) AEterna Zentaris Inc.
- Insider Monkey via Yahoo FinanceOct 09 23:31 PM
How do we determine whether General Motors Company (NYSE:GM) makes for a good investment at the moment? General Motors Company (NYSE:GM) was in 49 hedge funds' portfolios at the end of June.
- Insider Monkey via Yahoo FinanceOct 09 14:23 PM
DuPont de Nemours, Inc. NYSE:DD) has experienced a decrease in hedge fund sentiment of late. Overall hedge fund sentiment towards the stock is at its all time low.
- Insider Monkey via Yahoo FinanceOct 09 16:22 PM
How do we determine whether Ecolab Inc. (NYSE:ECL) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense ...
- Insider Monkey via Yahoo FinanceOct 09 14:41 PM
The last 12 months is one of those periods, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage points. In this article, we use our extensive ...
- Zacks via Yahoo FinanceOct 14 14:28 PM
In September, Aclaris completed a strategic review of its business and announced a restructuring plan to reform itself from a dermatology company to development stage biotech focusing on developing ...
- Zacks via Yahoo FinanceOct 10 14:11 PM
The recent FDA approval of Novartis AG’s NVS Beovu (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD) has put the spotlight on this promising space. What ...